

BEST AVAILABLE COPY

RECEIVED
CENTRAL FAX CENTER

JAN 13 2005

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)			
Applicant(s): <u>Black, et al.</u>		Docket No. <u>2003B085</u>	
Application No. <u>10/646,142</u>	Filing Date <u>August 22, 2003</u>	Examiner <u>Unassigned</u>	Group Art Unit <u>1764</u>
Invention: <u>Butadiene and Isobutylene Removal From Olefinic Streams</u>			
<p>I hereby certify that this <u>Transmittal, Transm. of IDS Statement, Form 1442 (5 pgs incl. cover)</u> (Identify type of correspondence) is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9306</u>) on <u>January 13, 2005</u> (Date)</p> <p><u>Shannon M. Borom</u> (Typed Printed Name of Person Signing Certificate) <u>Shannon M. Borom</u> (Signature)</p> <p>Note: Each paper must have its own certificate of mailing.</p>			

ADDRESS FOR USE ONLY: 07/01/2005, 01/01/2005, 01/01/2005
 Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
 UNDER THE Paperwork Reduction Act of 1995, no persons are required to furnish information to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all communications with this office)

Application Number	15666, 142
Filing Date	August 22, 2005
First Named Inventor	Michael Rasmussen
An Unit	1764
Examiner Name	Unassigned
Attorney Docket Number	2003B0066

Total Number of Pages in This Submission

4

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Addressed Communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment & Reply	<input type="checkbox"/> Division to Convert a Provisional Application	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Change of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Amendment/Extension(s)	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Request for Refund	<input checked="" type="checkbox"/> Other Enclosure(s) (Please Identify Enclosure)
<input type="checkbox"/> Express Amendment Request	<input type="checkbox"/> O.D. Number of CD(s)	<input type="checkbox"/> Transmittal of Item Identification Form 1-417 W.U. (2) References and Certificate of Transmittal
<input checked="" type="checkbox"/> Information Disclosure Statements		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Responses to Missing Parts/Incomplete Amendment		
<input type="checkbox"/> Responses to Missing Parts under NY filed 1.03 or 1.03		

Reference

CUSTOMER NO: 1366

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Diane L. Rasmussen-Lee (Maz, No. 34,311) Wasserman Chemical Company Lign Technology
Signature	<i>Diane L. Rasmussen-Lee</i>
Date	January 12, 2005

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being furnished transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage of first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1400, Alexandria, VA 22304-1400 on the date shown below:

Type of printed name	Signature	Date	January 12, 2005
	<i>Diane L. Rasmussen-Lee</i>		

This collection of information is required by 37 CFR 1.01. The information is required in order to (1) establish a correspondence with the USPTO, (2) establish a correspondence with the USPTO, (3) establish a correspondence with the USPTO, (4) establish a correspondence with the USPTO, (5) establish a correspondence with the USPTO, (6) establish a correspondence with the USPTO, (7) establish a correspondence with the USPTO, (8) establish a correspondence with the USPTO, (9) establish a correspondence with the USPTO, (10) establish a correspondence with the USPTO, (11) establish a correspondence with the USPTO, (12) establish a correspondence with the USPTO, (13) establish a correspondence with the USPTO, (14) establish a correspondence with the USPTO, (15) establish a correspondence with the USPTO, (16) establish a correspondence with the USPTO, (17) establish a correspondence with the USPTO, (18) establish a correspondence with the USPTO, (19) establish a correspondence with the USPTO, (20) establish a correspondence with the USPTO, (21) establish a correspondence with the USPTO, (22) establish a correspondence with the USPTO, (23) establish a correspondence with the USPTO, (24) establish a correspondence with the USPTO, (25) establish a correspondence with the USPTO, (26) establish a correspondence with the USPTO, (27) establish a correspondence with the USPTO, (28) establish a correspondence with the USPTO, (29) establish a correspondence with the USPTO, (30) establish a correspondence with the USPTO, (31) establish a correspondence with the USPTO, (32) establish a correspondence with the USPTO, (33) establish a correspondence with the USPTO, (34) establish a correspondence with the USPTO, (35) establish a correspondence with the USPTO, (36) establish a correspondence with the USPTO, (37) establish a correspondence with the USPTO, (38) establish a correspondence with the USPTO, (39) establish a correspondence with the USPTO, (40) establish a correspondence with the USPTO, (41) establish a correspondence with the USPTO, (42) establish a correspondence with the USPTO, (43) establish a correspondence with the USPTO, (44) establish a correspondence with the USPTO, (45) establish a correspondence with the USPTO, (46) establish a correspondence with the USPTO, (47) establish a correspondence with the USPTO, (48) establish a correspondence with the USPTO, (49) establish a correspondence with the USPTO, (50) establish a correspondence with the USPTO, (51) establish a correspondence with the USPTO, (52) establish a correspondence with the USPTO, (53) establish a correspondence with the USPTO, (54) establish a correspondence with the USPTO, (55) establish a correspondence with the USPTO, (56) establish a correspondence with the USPTO, (57) establish a correspondence with the USPTO, (58) establish a correspondence with the USPTO, (59) establish a correspondence with the USPTO, (60) establish a correspondence with the USPTO, (61) establish a correspondence with the USPTO, (62) establish a correspondence with the USPTO, (63) establish a correspondence with the USPTO, (64) establish a correspondence with the USPTO, (65) establish a correspondence with the USPTO, (66) establish a correspondence with the USPTO, (67) establish a correspondence with the USPTO, (68) establish a correspondence with the USPTO, (69) establish a correspondence with the USPTO, (70) establish a correspondence with the USPTO, (71) establish a correspondence with the USPTO, (72) establish a correspondence with the USPTO, (73) establish a correspondence with the USPTO, (74) establish a correspondence with the USPTO, (75) establish a correspondence with the USPTO, (76) establish a correspondence with the USPTO, (77) establish a correspondence with the USPTO, (78) establish a correspondence with the USPTO, (79) establish a correspondence with the USPTO, (80) establish a correspondence with the USPTO, (81) establish a correspondence with the USPTO, (82) establish a correspondence with the USPTO, (83) establish a correspondence with the USPTO, (84) establish a correspondence with the USPTO, (85) establish a correspondence with the USPTO, (86) establish a correspondence with the USPTO, (87) establish a correspondence with the USPTO, (88) establish a correspondence with the USPTO, (89) establish a correspondence with the USPTO, (90) establish a correspondence with the USPTO, (91) establish a correspondence with the USPTO, (92) establish a correspondence with the USPTO, (93) establish a correspondence with the USPTO, (94) establish a correspondence with the USPTO, (95) establish a correspondence with the USPTO, (96) establish a correspondence with the USPTO, (97) establish a correspondence with the USPTO, (98) establish a correspondence with the USPTO, (99) establish a correspondence with the USPTO, (100) establish a correspondence with the USPTO, (101) establish a correspondence with the USPTO, (102) establish a correspondence with the USPTO, (103) establish a correspondence with the USPTO, (104) establish a correspondence with the USPTO, (105) establish a correspondence with the USPTO, (106) establish a correspondence with the USPTO, (107) establish a correspondence with the USPTO, (108) establish a correspondence with the USPTO, (109) establish a correspondence with the USPTO, (110) establish a correspondence with the USPTO, (111) establish a correspondence with the USPTO, (112) establish a correspondence with the USPTO, (113) establish a correspondence with the USPTO, (114) establish a correspondence with the USPTO, (115) establish a correspondence with the USPTO, (116) establish a correspondence with the USPTO, (117) establish a correspondence with the USPTO, (118) establish a correspondence with the USPTO, (119) establish a correspondence with the USPTO, (120) establish a correspondence with the USPTO, (121) establish a correspondence with the USPTO, (122) establish a correspondence with the USPTO, (123) establish a correspondence with the USPTO, (124) establish a correspondence with the USPTO, (125) establish a correspondence with the USPTO, (126) establish a correspondence with the USPTO, (127) establish a correspondence with the USPTO, (128) establish a correspondence with the USPTO, (129) establish a correspondence with the USPTO, (130) establish a correspondence with the USPTO, (131) establish a correspondence with the USPTO, (132) establish a correspondence with the USPTO, (133) establish a correspondence with the USPTO, (134) establish a correspondence with the USPTO, (135) establish a correspondence with the USPTO, (136) establish a correspondence with the USPTO, (137) establish a correspondence with the USPTO, (138) establish a correspondence with the USPTO, (139) establish a correspondence with the USPTO, (140) establish a correspondence with the USPTO, (141) establish a correspondence with the USPTO, (142) establish a correspondence with the USPTO, (143) establish a correspondence with the USPTO, (144) establish a correspondence with the USPTO, (145) establish a correspondence with the USPTO, (146) establish a correspondence with the USPTO, (147) establish a correspondence with the USPTO, (148) establish a correspondence with the USPTO, (149) establish a correspondence with the USPTO, (150) establish a correspondence with the USPTO, (151) establish a correspondence with the USPTO, (152) establish a correspondence with the USPTO, (153) establish a correspondence with the USPTO, (154) establish a correspondence with the USPTO, (155) establish a correspondence with the USPTO, (156) establish a correspondence with the USPTO, (157) establish a correspondence with the USPTO, (158) establish a correspondence with the USPTO, (159) establish a correspondence with the USPTO, (160) establish a correspondence with the USPTO, (161) establish a correspondence with the USPTO, (162) establish a correspondence with the USPTO, (163) establish a correspondence with the USPTO, (164) establish a correspondence with the USPTO, (165) establish a correspondence with the USPTO, (166) establish a correspondence with the USPTO, (167) establish a correspondence with the USPTO, (168) establish a correspondence with the USPTO, (169) establish a correspondence with the USPTO, (170) establish a correspondence with the USPTO, (171) establish a correspondence with the USPTO, (172) establish a correspondence with the USPTO, (173) establish a correspondence with the USPTO, (174) establish a correspondence with the USPTO, (175) establish a correspondence with

BEST AVAILABLE COPY

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b), 1.97(c), or 1.97(d)			Attny. Docket No. 2003B085
In Re Application of: Risch et al.			
U.S. Serial No. 10/646,142	Filing Date August 22, 2003	Examiner Unassigned	Group Art Unit 1764

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RECEIVED
CENTRAL FAX CENTER**

JAN 13 2005

37 CFR § 1.97(b)

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of:

1. a Final Action under § 1.113,
2. a Notice of Allowance under § 1.311, or
3. an action that otherwise closes prosecution in the application,

and is accompanied by either:

- ☐ the fee as set forth in § 1.17(p), or
- ☐ the following statement under § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

37 CFR § 1.97(d)

- ☐ The Information Disclosure Statement submitted herewith is being filed after a Final Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicant hereby request consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith.

☒ Legible copies of the references are enclosed, where required.

☐ This application is a:

☐ Continuation / Divisional,


☐ Continuation-in-Part,

of U.S.S.N. _____. Copies of the cited references are
☒ enclosed; ☐ not enclosed. References are available in the parent application(s) if not enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account Number 05-1712. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: January 13, 2005


Diane L. Kilpatrick-Lee
Attorney for Applicants
Registration No. 56,211

ExxonMobil Chemical Company
Law Technology
P.O. Box 2149
Baytown, Texas 77522-2149
(281) 834-1743 (Voice)
(281) 834-2995 (Fax)

BEST AVAILABLE COPY RECEIVED

EXXONMOBIL CENTRAL FAX CENTER

2818347413 P.05
SHEET 1 OF 1JAN-13-2005 00:28
FORM - 1449

JAN 13 2005

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

2003B085

10/646,142

APPLICANT

Risch et al.

FILING DATE

GROUP

August 22, 2003

1764

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	2003/100811	05/29/03	Dakka et al	585	510	
	AB	4,645,576	02/24/87	Takezono et al	203	30	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBL. DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)

	AP	
	AQ	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next comment to applicant